The FDA approved a supplemental new drug application on valacyclovir (Valtrex), allowing a shorter course of treatment
Day 1 Recap: 2024 Fall Clinical Dermatology Conference for PAs and NPs
The Cutaneous Connection: A Reminder of Patient Impact
Rapid HS Pearls: Drug Data and Wound Care
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment
Dupilumab Treatment in Pediatric Atopic Dermatitis: Consistent Improvement Across Anatomical Regions
QUIZ RECAP: Treatment and Management of Skin Cancer